基于Ⅰ类包膜病毒膜融合机制的肽类抗病毒药物研究进展  

Membrane fusion mechanism based anti-class Ⅰ enveloped virus peptides:research advances

作　　者：孟广鹏 梁国栋 张培宇 王潮 刘克良[1,2] MENG Guang-peng;LIANG Guo-dong;ZHANG Pei-yu;WANG Chao;LIU Ke-liang(School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, China;Institute of Pharmacology and Toxicology, Militry Medical Institute, Military Academy of Sciences, Beijing 100850, China)

机构地区：[1]沈阳药科大学制药工程学院,沈阳110016 [2]军事科学院军事医学研究院毒物药物研究所,北京100850

出　　处：《国际药学研究杂志》2017年第11期995-1005,共11页Journal of International Pharmaceutical Research

摘　　要：病毒性疾病已成为影响人类健康的重大威胁之一,其中,由Ⅰ类包膜病毒引起的疾病传播甚广,危害极大。研究表明,Ⅰ类包膜病毒如1型人类免疫缺陷病毒(HIV-1)、中东呼吸综合征冠状病毒和流感病毒等在进入宿主细胞的过程中会形成六股螺旋结构,特异性地抑制其形成过程可阻断病毒与宿主细胞膜的融合,从而达到抑制病毒增殖的效果。基于Ⅰ类包膜病毒膜融合机制的肽类抗病毒药物具有生物活性高、副作用小及特异性强等优点,正逐渐成为肽类抗病毒药物研究的热点。本文对近年来基于Ⅰ类包膜病毒膜融合机制的肽类抗病毒药物的研究进展进行了较为系统的综述。Viral diseases have become one of the major threats to human health. Among them,the diseases caused by the classⅠenveloped viruses spread widely with great harm. It has been known that the class I enveloped viruses,such as the human immunodeficiency virus type 1,Middle East respiratory syndrome coronavirus and influenza virus,could form six helix bundles when they enter into the host cells. Therefore specifically inhibiting the formation of six helix bundle could block the membrane fusion of the viruses and host cells,so as to suppress the viral multiplication. The membrane fusion mechanism of classⅠenveloped virus based antiviral peptides have displayed many advantages,including high potency,less side-effect and toxicity as well as excellent specificity,and have increasingly attracted attention in the antiviral peptide drug research area. In this paper,we systematically review the development and application of the membrane fusion mechanism based anti-classⅠenveloped virus peptides in recent years.

关 键 词：多肽 Ⅰ类包膜病毒 1型人类免疫缺陷病毒(HIV-1) 广谱抗病毒 

分 类 号：R978.7[医药卫生—药品]